Ventyx Biosciences initiated at outperform at Credit Suisse on immune system candidates

Retrieved on: 2022-05-09 21:04:30

Tags for this article:

Click the tags to see associated articles and topics

Ventyx Biosciences initiated at outperform at Credit Suisse on immune system candidates. View article details on hiswai:

Excerpt

Credit Suisse has initiated Ventyx Biosciences (VTYX) with an outperform rating citing the company's Tyrosine kinase 2 (TYK2) inhibitor VTX958 as ...

Article found on: seekingalpha.com